FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324609475> ?p ?o ?g. }

• W2324609475 endingPage "373" @default.
• W2324609475 startingPage "373.2" @default.
• W2324609475 abstract "<h3>Background</h3> Sirukumab (formerly named CNTO136) is a human mAb that binds with high affinity to the cytokine IL-6. In the proof of concept part (Part A) of this multicenter, randomized, double blind, PBO controlled, phase 2 study, 100mg sirukumab SC injections q2w were generally well tolerated and efficacious <h3>Objectives</h3> The phase 2 dose-ranging Part B was initiated after Part A to determine efficacious and safe sirukumab dose regimens. <h3>Methods</h3> In Part B, pts with active RA despite MTX were randomized equally to: (1) PBO q2wk at wks 0–10, then sirukumab 100 mg q2wk at wks12–24; (2) sirukumab 100 mg q2wk at wks 0–24; (3) sirukumab 100 mg q4wk at wks 0–24; (4) sirukumab 50 mg q4wk at wks 0–24; or (5) sirukumab 25 mg q4wk at wks 0–24. As reported previously, the primary endpoint (ACR50 response at wk 12) was achieved by the 100 mg q2wk and 50 mg q4wk doses. We now report specific changes observed through wk12 in the Health Assessment Questionnaire disability index (HAQ-DI), the physical component summary (PCS) score of the Short Form-36 (SF-36) scales, and individual ACR core components other than HAQ-DI. Two improvement thresholds (≥0.25 and ≥0.30) were used to define HAQ-DI response. Clinical response was assessed using the Disease Activity Score (employing 28 joints and C-reactive protein, DAS28-CRP) and Clinical Disease Activity Index (CDAI). The study was only powered for the primary endpoint. An intent-to-treat analysis of pts according to original treatment assignments was conducted, with imputation of missing data by carrying forward the last observation and treatment failure rules for non-responders. <h3>Results</h3> In Part B, 151 pts were randomized and treated. At baseline, mean age: 53±11 yrs, mean weight: 69±15 kg, mean DAS28 (CRP): 5.9±0.9, and median serum CRP: 1.7 mg/dL. Mean baseline HAQ-DI scores (1.54±0.64) were comparable between treatment groups; mean SF-36 PCS score (31.55±7.78) was notably below the general population norm. At wk12, a higher proportion of pts achieved HAQ-DI response, significantly greater improvement in HAQ-DI was observed in the combined sirukumab group (mean±sd: 0.42±0.53) compared to PBO (0.15±0.56) (p=0.012). No apparent sirukumab dose response was observed. HAQ-DI response was observed as early as wk2 and increased over time through wk24 in all 5 treatment groups. At wk12, greater improvement in SF-36 PCS score was observed in the combined sirukumab group compared with PBO (p=0.038). Also, statistically significant improvement in the combined sirukumab group vs. PBO was observed for each of the ACR core components, except for tender joint count, which trended toward improvement (p=0.06). Pain (p=0.010), physician global (p=0.005), and CRP (p<0.001) appeared to show the greatest short-term response to sirukumab treatment. Significant clinical improvement in the combined sirukumab group vs. PBO was evident at wk12 when assessed either by change from baseline in DAS28 (CRP) (p<0.001) or by change in the CDAI score (p=0.009). <h3>Conclusions</h3> In this Phase 2 study of patients with active RA despite MTX therapy, sirukumab in combination with MTX, improved physical function as well as reduced multiple other signs and symptoms of RA. <h3>Disclosure of Interest</h3> B. Hsu: None Declared, C.-F. Chiou: None Declared, S. Sheng Employee of: Janssen Research & Development, LLC, J. Smolen Grant/Research support from: Investigators for Janssen Research & Development, LLC sponsored clinical study, M. Weinblatt Grant/Research support from: Investigators for Janssen Research & Development, LLC sponsored clinical study" @default.
• W2324609475 created "2016-06-24" @default.
• W2324609475 creator A5035556723 @default.
• W2324609475 creator A5047117557 @default.
• W2324609475 creator A5051127450 @default.
• W2324609475 creator A5055685727 @default.
• W2324609475 creator A5081225826 @default.
• W2324609475 date "2013-06-01" @default.
• W2324609475 modified "2023-09-27" @default.
• W2324609475 title "FRI0181 Sirukumab, a human anti-IL-6 monoclonal antibody, improves physical function in patients with active ra despite methotrexate therapy: Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study" @default.
• W2324609475 doi "https://doi.org/10.1136/annrheumdis-2012-eular.2638" @default.
• W2324609475 hasPublicationYear "2013" @default.
• W2324609475 type Work @default.
• W2324609475 sameAs 2324609475 @default.
• W2324609475 citedByCount "1" @default.
• W2324609475 countsByYear W23246094752014 @default.
• W2324609475 crossrefType "journal-article" @default.
• W2324609475 hasAuthorship W2324609475A5035556723 @default.
• W2324609475 hasAuthorship W2324609475A5047117557 @default.
• W2324609475 hasAuthorship W2324609475A5051127450 @default.
• W2324609475 hasAuthorship W2324609475A5055685727 @default.
• W2324609475 hasAuthorship W2324609475A5081225826 @default.
• W2324609475 hasConcept C126322002 @default.
• W2324609475 hasConcept C142724271 @default.
• W2324609475 hasConcept C168563851 @default.
• W2324609475 hasConcept C203092338 @default.
• W2324609475 hasConcept C204787440 @default.
• W2324609475 hasConcept C27081682 @default.
• W2324609475 hasConcept C2776312127 @default.
• W2324609475 hasConcept C2781059491 @default.
• W2324609475 hasConcept C2991744798 @default.
• W2324609475 hasConcept C71924100 @default.
• W2324609475 hasConcept C90924648 @default.
• W2324609475 hasConceptScore W2324609475C126322002 @default.
• W2324609475 hasConceptScore W2324609475C142724271 @default.
• W2324609475 hasConceptScore W2324609475C168563851 @default.
• W2324609475 hasConceptScore W2324609475C203092338 @default.
• W2324609475 hasConceptScore W2324609475C204787440 @default.
• W2324609475 hasConceptScore W2324609475C27081682 @default.
• W2324609475 hasConceptScore W2324609475C2776312127 @default.
• W2324609475 hasConceptScore W2324609475C2781059491 @default.
• W2324609475 hasConceptScore W2324609475C2991744798 @default.
• W2324609475 hasConceptScore W2324609475C71924100 @default.
• W2324609475 hasConceptScore W2324609475C90924648 @default.
• W2324609475 hasIssue "Suppl 3" @default.
• W2324609475 hasLocation W23246094751 @default.
• W2324609475 hasOpenAccess W2324609475 @default.
• W2324609475 hasPrimaryLocation W23246094751 @default.
• W2324609475 hasRelatedWork W1963737685 @default.
• W2324609475 hasRelatedWork W2054110146 @default.
• W2324609475 hasRelatedWork W2248005408 @default.
• W2324609475 hasRelatedWork W2317645263 @default.
• W2324609475 hasRelatedWork W2507295142 @default.
• W2324609475 hasRelatedWork W2516167102 @default.
• W2324609475 hasRelatedWork W2767151183 @default.
• W2324609475 hasRelatedWork W3159250744 @default.
• W2324609475 hasRelatedWork W4256514411 @default.
• W2324609475 hasRelatedWork W4292236216 @default.
• W2324609475 hasVolume "71" @default.
• W2324609475 isParatext "false" @default.
• W2324609475 isRetracted "false" @default.
• W2324609475 magId "2324609475" @default.
• W2324609475 workType "article" @default.